CINECA IRIS Institutional Research Information System

BORELLI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.157
AS - Asia 1.085
EU - Europa 848
SA - Sud America 176
Continente sconosciuto - Info sul continente non disponibili 79
AF - Africa 76
OC - Oceania 1
Totale 4.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.106
SG - Singapore 417
IT - Italia 341
CN - Cina 264
HK - Hong Kong 150
BR - Brasile 134
VN - Vietnam 101
SE - Svezia 93
GB - Regno Unito 86
DE - Germania 78
FR - Francia 63
BG - Bulgaria 46
CA - Canada 37
IN - India 27
FI - Finlandia 26
CI - Costa d'Avorio 25
PL - Polonia 23
BD - Bangladesh 20
JP - Giappone 19
RU - Federazione Russa 19
AR - Argentina 17
TR - Turchia 15
NG - Nigeria 14
AT - Austria 12
ID - Indonesia 11
NL - Olanda 11
ES - Italia 10
UA - Ucraina 10
MX - Messico 9
EC - Ecuador 7
MA - Marocco 7
PH - Filippine 7
CZ - Repubblica Ceca 6
IQ - Iraq 6
KR - Corea 6
CO - Colombia 5
SA - Arabia Saudita 5
SN - Senegal 5
CH - Svizzera 4
CL - Cile 4
KG - Kirghizistan 4
NP - Nepal 4
PK - Pakistan 4
VE - Venezuela 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
IE - Irlanda 3
LT - Lituania 3
MY - Malesia 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
TN - Tunisia 3
UZ - Uzbekistan 3
AL - Albania 2
AO - Angola 2
DZ - Algeria 2
ET - Etiopia 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
LY - Libia 2
AZ - Azerbaigian 1
BF - Burkina Faso 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
MT - Malta 1
NA - Namibia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
RO - Romania 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.344
Salva come PNG Salva come JPEG
Città #
Ashburn 305
Singapore 231
Dallas 197
San Jose 168
Fairfield 161
Hong Kong 144
Santa Clara 144
Chandler 107
Woodbridge 105
Seattle 76
New York 64
Shanghai 62
Wilmington 62
Cambridge 54
Milan 51
London 49
Los Angeles 47
Beijing 45
Sofia 45
Florence 42
Houston 42
Boardman 39
Ho Chi Minh City 30
Munich 30
Pisa 28
Ann Arbor 26
Abidjan 25
Hanoi 25
Lawrence 23
Princeton 23
Frankfurt am Main 20
Lauterbourg 19
Bremen 18
Warsaw 18
Tokyo 17
Medford 16
Rome 15
Lagos 14
Ogden 14
Redondo Beach 14
Serra 14
Cascina 13
Ottawa 13
Turku 13
Hefei 12
São Paulo 12
Columbus 11
Council Bluffs 11
Helsinki 11
Istanbul 11
Vienna 11
Des Moines 10
Montreal 10
Orem 10
Seacroft 10
Dearborn 9
Genoa 9
Nanjing 8
Buffalo 6
Chicago 6
Fuzhou 6
Kent 6
Kunming 6
Phoenix 6
Redwood City 6
Seoul 6
Verona 6
Atlanta 5
Baghdad 5
Boston 5
Brooklyn 5
Chennai 5
Dakar 5
Dhaka 5
Paris 5
Rio de Janeiro 5
Toronto 5
Turin 5
Carrara 4
Curitiba 4
Denver 4
Dong Ket 4
Düsseldorf 4
Lancaster 4
Lucca 4
Nanchang 4
Palermo 4
Poplar 4
San Diego 4
Brent 3
Cairo 3
Capannori 3
Da Nang 3
Fortaleza 3
Gargallo 3
Guangzhou 3
Hải Dương 3
Kyiv 3
Marseille 3
Nuremberg 3
Totale 2.999
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 195
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 194
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 184
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 180
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 179
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 172
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 170
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 168
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 165
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 164
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 159
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 158
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 155
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 154
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 145
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 139
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 135
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 132
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 130
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 130
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 130
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial) 129
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 124
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 122
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 107
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 101
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 100
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials 90
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials 67
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 33
Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer 23
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer 22
Totale 4.422
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.122
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.122
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022182 0 2 2 0 33 32 4 5 10 20 17 57
2022/2023433 33 69 23 39 48 47 22 25 59 3 58 7
2023/2024348 26 37 54 33 47 44 19 11 6 6 40 25
2024/20251.023 18 47 25 65 93 126 75 41 106 124 101 202
2025/20261.543 102 154 185 144 168 113 206 91 110 144 88 38
2026/2027140 105 35 0 0 0 0 0 0 0 0 0 0
Totale 4.422